Skip to main content

Table 1 Characteristics of each included trials

From: Efficacy and safety of radiofrequency treatment for improving knee pain and function in knee osteoarthritis: a meta-analysis of randomized controlled trials

References

Country

No. of Patients (RF/Control)

Treatment Gender (M/F)

Control Gender (M/F)

Mean age (years) (RF/Control)

Kellgren-Lawrence grade

BMI (RF/Control)

Disease courses (years) (RF/Control)

Treatment pain score baseline

Control pain score baseline

[21]

Korea

17/18

2/15

3/15

67.9/66.5

NA

26.2/26.5

6.3/7.4

7.82 (1.38)

7.72 (0.75)

[22]

China

17/19

NA

NA

NA

1–3

NA

NA

7.26 (1.34)

7.19 (1.57)

[23]

Iran

24/26

11/13

10/16

57.0/60.6

3–4

NA

NA

7.08 (1.41)

7.11 (1.03)

[24]

China

31/31

NA

NA

NA

NA

NA

NA

7.25 (1.33)

7.21 (1.58)

[25]

China

27/27

7/20

9/18

62.2/62.4

2–4

NA

5.01/4.96

7.12 (1.08)

7.14 (1.03)

[35]

China

12/12

5/7

3/9

51.7/54.0

1–3

NA

NA

8.25 (0.62)

8.16 (0.72)

[26]

Turkey

37/36

7/30

9/25

64.0/64.0

2–3

23.5/22.9

5/5

NA

NA

[27]

China

45/47

17/28

20/27

66.1/65.9

NA

24.5/24.9

8.2/8.2

6.53 (1.10)

6.38 (1.03)

[28]

China

49/47

12/37

11/36

56.5/61.5

3–4

NA

3.04/2.96

7.3 (1.2)

7.3 (1.4)

[29]

Egypt

30/30

9/21

12/18

62.0/56.9

2–4

32.0/30.2

7.6/5.7

7.07 (0.2)

7.07 (0.2)

[30]

America

76/75

26/50

26/49

63.0/66.0

3–4

30.6/30.4

10.7/8.6

7.3 (1.2)

7.2 (1.0)

[31]

UK

15/15

6/9

6/9

63.0/63.0

2–4

31.0/31.0

5.6/4.3

6.3 (1.2)

5.8 (1.2)

[32]

America

89/88

37/52

34/54

63.3/63.1

2–3

32.2/30.5

7.5/8.8

NA

NA

[33]

China

26/27

10/16

12/15

59.5/60.9

3–4

24.6/25.8

2.7/2.9

6.46 (1.14)

6.37 (0.93)

[34]

Italy

8/8

2/6

3/5

70.4/70.9

NA

29.5/29.6

9.6/10.4

8.25 (0.70)

8.0 (1.19)

  1. RF, radiofrequency; M, male; F, female; BMI, body mass index; NA, not applicable